| Rachel E Kay, OT | |
|
1238 Girard Blvd Ne, Albuquerque, NM 87106-1860 | |
| (505) 850-5400 | |
| Not Available |
| Full Name | Rachel E Kay |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 1238 Girard Blvd Ne, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205006269 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 3681 (New Mexico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rachel E Kay, OT 1238 Girard Blvd Ne, Albuquerque, NM 87106-1860 Ph: (505) 850-5400 | Rachel E Kay, OT 1238 Girard Blvd Ne, Albuquerque, NM 87106-1860 Ph: (505) 850-5400 |
News Archive
The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
Scientists showed that people who have a variant of a longevity gene, called KLOTHO, have improved brain skills such as thinking, learning and memory regardless of their age, sex, or whether they have a genetic risk factor for Alzheimer's disease.
Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir's existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.
Scientists have discovered a new cellular pathway that can promote and support the growth of cancer cells. In a mouse model of melanoma, blocking this pathway resulted in reduction of tumor growth.
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has approved ABILIFY MAINTENA (aripiprazole) for extended- release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia.
› Verified 6 days ago
Sarah Day, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2722 Santa Monica Ave Se, Albuquerque, NM 87106 Phone: 505-702-6452 | |
Leslie Price, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2929 Coors Blvd Nw Ste 100, Albuquerque, NM 87120 Phone: 505-836-4899 Fax: 505-836-4844 | |
Diana Drawe, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 505 Elm St Ne, Albuquerque, NM 87102 Phone: 505-727-4725 | |
Tyler Paul Mason, MOTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3830 Commons Ave Ne, Albuquerque, NM 87109 Phone: 502-542-4123 | |
Rebecca S Starrett, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5100 Marna Lynn Ave Nw, Petroglyph Es, Albuquerque, NM 87114 Phone: 505-898-0923 | |
Action Works Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1104 Idlewilde Ln Se, Albuquerque, NM 87108 Phone: 505-266-5724 | |
Sidney T Alley, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 601 4th St Sw, Coronado Complex, Albuquerque, NM 87102 Phone: 505-247-1012 |